Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP…
MP0317 demonstrates tumor-localized CD40 activation in tumor biopsies through target occupancy and immune cell activation MP0317 demonstrates a favorable safety profile across Q3W and Q1W…